9 The Future Prospects for Fungicides and Fungal Disease Control

Key Points

- The incessant rise in food demand means that all reliable methods of crop protection must be deployed at full efficiency.
- Global warming and biosecurity failures are likely to further impact crop protection.
- Many existing fungicides are likely to be phased out due to regulatory challenges.
- Fungicide resistance demands that resistance management strategies are used this increases the need for new actives with new MOAs.
- The pipeline for new actives is working but at ever-increasing cost. Genomics and molecular modelling are likely to have an increasing impact.
- IDM will become standard practice. Better methods to select genetically resistant crops will bear fruit.
- Transgenic (GM) methods to deliver disease resistance have not developed due to public reluctance to accept transgenic crops.
- Developing genetically modified (GM) traits to replace or more likely supplement fungicides will require a major research effort.

Food Demand and Disease Threats

The world's population is growing at a faster pace than ever before and looks set to increase until at least 2050. The population needs to be fed and needs somewhere to live. Hence more food needs to be grown on less land with less water. To reduce the levels of food insecurity that already exist in parts of the world and to prevent food deficits occurring in more productive regions, efficient and effective methods of crop production must be introduced and maintained.

There are many reasons to believe that the disease pressure on the crops will increase. Global warming will have varied and rather unpredictable effects on crop diseases (Carlton *et al.*, 2012; West *et al.*, 2012) but generally will decrease food security. Global warming and ever-increasing international travel and trade will reduce or even eliminate the power of national quarantine agencies to keep exotic pathogens out of their countries. History teaches that plant pathogenic fungi will always challenge our ability to produce food in quantity and of an acceptable quality. In adopting the highly efficient practice of crop monoculture, the risk of crop failure from plant diseases has increased from something of occasional and marginal importance that could be sustained in an unsophisticated society, to a serious and continual problem often resulting in devastating yield losses and widespread social disruption.

Although the introduction of monocultures provided crop pathogens with an ideal environment in which to multiply, the situation in some crops was exacerbated by techniques that were subsequently adopted to manage other problems. In cereals, the drive to increase yield through the use of improved varieties and higher fertilizer inputs highlighted the value of good weed control. The ensuing spiral towards higher yields through the increasing use of fertilizers and herbicides eventually hit the yield-limiting factor of plant disease. Fungicides allowed yet more fertilizer to be used, to achieve even greater yields.

The effects of crop disease cannot be trivialized because they are never far away. Current estimates suggest that without fungicides we would lose up to one-third of yield, depending on the crop. In some circumstances, total loss is possible. Even in Europe, famine and food shortage were only a few harvests ago and the threat of their return has not disappeared. This reality necessitates the use of crop protection management systems that contain fungicides as an integral component.

The development and use of fungicides in crop protection is a success story. It is a story that has developed from their earliest and crude application in agriculture and horticulture, through a series of technological evolutionary steps, to a point where products are able to exert safe, broad-spectrum control for extended periods, or to work precisely to protect against attack by specific pathogens, or even to influence the host itself to combat infection. However, the process of improvement in crop disease management continues and the next 20 years are likely to witness even greater changes in fungicide technology and use.

Loss of Existing Fungicides

We have already seen (Chapter 8) that regulations initiated in Europe have led to the withdrawal of many active compounds. The ever-tightening regulatory demands, at least in Europe, will increase the pressure on the remaining compounds. The DMI group is already under serious threat and its loss could have a massive impact on the quantity and quality of food production worldwide.

Fungicide resistance preceded the withdrawal of the MBC class of fungicides by some years. Other fungicides afflicted significantly by resistance (see Chapter 6), including the DMI, QoI, PA, CAA and SDHI groups, remain in use. Indeed, predictions that QoIs would become useless through resistance have proved very wide of the mark. Instead fungicide resistance management strategies have ensured their continued use. The strategies involved mixtures and alternations of fungicides. Hence there is a strong demand for new fungicides to fulfil roles in resistance management.

The Discovery Process

The pace of fungicide discovery shows no sign of slowing up (Chapter 4). Instead, new actives and new MOAs are being as released as fast as ever. This may be because the consolidation of fungicide discoveries into ever fewer but larger companies (Syngenta, BASF and Bayer) has increased the efficiency of the discovery processes.

Nonetheless, the low-hanging fruit have been picked. The unique biomolecules in fungi, particularly the ergosterol biosynthesis pathway, have been thoroughly examined for fungicide targets. It seems inevitable that newer fungicides will require a more expensive discovery pathway than existing ones.

Genomics has not yet had a profound impact on the processes of fungicide discovery. However we now have the situation in which the genome sequences of all relevant organisms, both the target fungi and the non-targets, are obtained or could be with only trivial effort. It is therefore possible to imagine a genomics-led discovery process in which molecules will be designed only to bind and inhibit key enzymes in the fungi and have no effect on non-target organisms. This is theoretically more straightforward than designing a pharmaceutical for a non-infectious human disease. Such a development would require a major effort in genomics and automated protein structure prediction.

Genetic Disease Control

Crop diseases are exceptional events, as all plants have natural defence systems to repel most fungal challenges. Molecular plant breeding allows breeders to combine in one cultivar all the best alleles of disease resistance genes as well as other desirable traits, as long as markers for the genes of interest have been discovered. Despite the fact that genome sequences for many major crops are now available, this process has not progressed as fast as was predicted and, to date, only major resistance gene markers are in general use. The quantitative and minor genes typical of so many resistance phenotypes have been harder to pin down. Developing the understanding of pathogenicity mechanisms in more fungi and better genomic resources for more crops will accelerate this process.

Transgenic (GM) Disease Control

Mechanisms that permit the transfer of alien genes into plants have been available for over 25 years (Binns, 2002). Several characteristics have been researched in breeding programmes, such as nitrogen fixation, drought tolerance and the modification of protein components and their storage. The GM technologies were new and deemed to be commercially risky, so the chemical companies pursued only the biggest markets with the greatest profit potential. Hence the great majority of GM crops released to date involve genes for herbicide resistance and for insect tolerance. Resistance to viruses has also been successfully deployed.

As long ago as 1991, it was shown that the expression of alien genes controlling hydrolytic enzyme activity in transgenic tobacco and oilseed rape resulted in increased resistance to infection by *R. solani* (Broglie *et al.*, 1991). Many other traits have been examined and tested in laboratory-scale experiments but, to date, no commercial crops with transgenic disease resistance have been released (Logemann *et al.*, 1992; Toubart *et al.*, 1992; Gurr and Rushton, 2005).

The reasons for this glaring failure are partly scientific but also partly political. Developing a GM disease resistance trait is beset with many of the same difficulties as developing a new fungicide; the GM trait should generate good levels of disease resistance against a wide spectrum of pathogens and should be safe. Research was carried out on a wide scale in both university and chemical company laboratories. Indeed, many chemical companies bought seed companies so as to have a route to market the new disease resistance traits.

The first major disease resistance genes (R-genes) were cloned and analysed around 1994 (Jones *et al.*, 1994; Hammond-Kosack and Jones, 1997). The first thought was to express these genes in other plants to see whether they conferred resistance. However, it soon became apparent that R-genes were very specific and only worked in the species or at best the family from which they were derived (Gurr and Rushton, 2005). Hence this route has limited spectrum and has not attracted sufficient commercial interest.

Activation of resistance genes during infections leads to the production of a defence response which somehow kills the fungus (Anderson *et al.*, 2005). So-called PR (pathogenesis related) genes producing chitinases and glucanases were among the induced genes. The release of active oxygen was also involved. Hence many people pursued the idea that enhanced expression of these genes would lead to resistance. This strategy has been undermined to some extent by the growth reductions seen in plants expressing PR proteins that outweigh the potential benefit of disease resistance.

Another line of thought was to deploy antifungal proteins in transgenic plants (Jach *et al.*, 1995). These are diverse proteins with potent activity against several fungi. However such traits have failed the very stringent animal toxicology tests.

The latest research involves the use of RNA interference to inhibit the expression of fungal genes essential for infection (Nowara *et al.*, 2010; Duan *et al.*, 2012; Panwar et al., 2013). The mRNA is targeted by a short RNA molecule that is complementary in sequence. This creates a short stretch of double-stranded RNA (dsRNA). dsRNA is efficiently detected in plants by a set of enzymes that cleave the RNA and inactivate it before it is translated into proteins. This is a very promising technology that can be delivered either by direct delivery of RNA molecules instead of a chemical fungicide or via expression of the RNA in the infected plant tissue. The proponents of this technology predict its widespread use in the next 5–15 years. It seems likely that a combination of chemical, conventional genetic and GM traits using antifungal genes, signalling molecules and RNA interference will become the norm in the next decades.

Developments in GM disease resistance have so far failed to progress to market. The scientific questions are tough but surely would have been solved had the level of investment present through the 1980s and 1990s been maintained. However the backlash against GM products that emerged in Europe in 1996 following the 'mad-cow disease' outbreaks caused both public- and private-sector organizations to cut back investments in this area. GM herbicide- and insect-resistant crops have been grown on a huge area and no deleterious effects have been reported. Nonetheless, no relaxation of the regulations has been forthcoming albeit there are signs of reduced anxiety at the moment. We will see whether investment now increases to exploit the potential of the GM disease resistance market.

Market Development

The last decades have seen a major consolidation in the fungicide market. Currently only three major companies are engaged in the full range from discovery to marketing.

A further merger within these companies seems unlikely. It is also hard to imagine how a new company could enter the market for conventional fungicides. Generic manufacturers are increasing in number and global importance, especially as China, India and many other tropical and semi-tropical countries become both fungicide users and manufacturers. There is the potential for new companies to enter the arena through the provision of GM traits, but the extremely demanding regulatory burden makes this unlikely. Clearly, the future for fungicide discovery is firmly fixed within a few very large companies.

References

- Anderson, J.P., Thatcher, L.F. and Singh, K.B. (2005) Plant defence responses: conservation between models and crops. *Functional Plant Biology* 32(1), 21–34.
- Binns, A.N. (2002) t-DNA of Agrobacterium tumefaciens: 25 years and counting. Trends in Plant Science 7(5), 231–233.
- Broglie, K., Chet, I., Holliday, M., Cressman, R., Biddle, P., *et al.* (1991) Transgenic plants with enhanced resistance to the fungal pathogen *Rhizoctonia solani*. *Science* 254(5035), 1194–1197.
- Carlton, R.R., West, J.S., Smith, P. and Fitt, B.D.L. (2012) A comparison of GHG emissions from UK field crop production under selected arable systems with reference to disease control. *European Journal of Plant Pathology* 133(1), 333–351.
- Duan, C.G., Wang, C.H. and Guo, H.S. (2012) Application of RNA silencing to plant disease resistance. *Silence* 3(1), 5.
- Gurr, S.J. and Rushton, P.J. (2005) Engineering plants with increased disease resistance: what are we going to express? *Trends in Biotechnology* 23(6), 275–282.
- Hammond-Kosack, K.E. and Jones, J.D.G. (1997) Plant disease resistance genes. *Annual Review of Plant Physiology and Plant Molecular Biology* 48(1), 575–607.
- Jach, G., Görnhardt, B., Mundy, J., Logemann, J., Pinsdorf, E., *et al.* (1995) Enhanced quantitative resistance against fungal disease by combinatorial expression of different barley antifungal proteins in transgenic tobacco. *The Plant Journal* 8(1), 97–109.
- Jones, D., Thomas, C., Hammond-Kosack, K., Balintkurti, P. and Jones, J. (1994) Isolation of the tomato cf-9 gene for resistance to *Cladosporium fulvum* by transposon tagging. *Science* 266(5186), 789–793.
- Logemann, J., Jach, G., Tommerup, H., Mundy, J. and Schell, J. (1992) Expression of a barley ribosome-inactivating protein leads to increased fungal protection in transgenic tobacco plants. *Bio/Technology* 10, 305–308.
- Nowara, D., Schweizer, P., Gay, A., Lacomme, C., Shaw, J., *et al.* (2010). HIGS: host-induced gene silencing in the obligate biotrophic fungal pathogen *Blumeria graminis*. *Plant Cell* 22(9), 3130–3141.
- Panwar, V., McCallum, B. and Bakkeren, G. (2013) Host-induced gene silencing of wheat leaf rust fungus *Puccinia triticina* pathogenicity genes mediated by the barley stripe mosaic virus. *Plant Molecular Biology* 81(6), 595–608.
- Toubart, P., Desiderio, A., Salvi, G., Cervone, E., Daroda, L., et al. (1992) Cloning and characterisation of the gene encoding the endopolygalacturonase-inhibiting protein (PGIP) of *Phaseolus vulgaris* 1. *The Plant Journal* 2(3), 367–373.
- West, J.S., Townsend, J.A., Stevens, M. and Fitt, B.D.L. (2012) Comparative biology of different plant pathogens to estimate effects of climate change on crop diseases in Europe. *European Journal of Plant Pathology* 133(1), 315–331.

This page intentionally left blank

Index

acceptable daily intake (ADI) 169 acylalanines 142 adjuvants 66 Alternaria sp. 93 mali 35 amidinium 60-62 amino acid synthesis 94 anilinopyrimidines 94 apple scab (VENTIN) 6, 16, 35, 42, 49, 64, 93, 94, 102, 111, 113 Ascomycota 1, 13-16 Asia 42 ASM (acibenzolar-S-methyl) 107-108 Aspergillus nidulans 50 niger 50 Australia 2, 42 azanaphthalenes 95 azoxystrobin 92

barley powdery mildew (ERYSGH) 30, 41, 60-61, 64, 92, 93, 94, 104, 127 fungicide resistance 123-124, 139 BASF 10, 36 Basidiomycota 1, 16 Bayer CropScience 6, 10, 36 bean anthracnose (Colletotrichum lindemuthianum) 16 benomyl 85 resistance 136-137 benzamides 87 benodanil 88-89 benzimidazole 85-87, 123 Bion 107-108 biotrophs 17 bird toxicity 166 bixafen 90 black sigatoka (MYCFIJ) 49, 64, 102, 110-111 fungicide resistance 132 Bordeaux mixture 6, 34, 173 boscalid 89-90 BOTCIN (Botrytis cinerea) 34, 40, 42, 49, 93, 94, 95, 102, 104, 111, 113

fungicide resistance 132, 140 Botrytis cinerea 34, 40, 42, 49, 93, 94, 95, 102, 104, 111, 113 fungicide resistance 132, 140 breakdown 165 brown rust (PUCCRT) 8, 64, 89, 90 bunt (*Tilletia tritici*) 5, 6–7 bupirimate 83

C14-demethylation inhibitors 59 captan 112-113 carbendazim 85, 87 carbocation mimicry 60-62 carboxin 88 carboxylic acid amides (CAA) 104-105 resistance 129, 142, 178 cell wall biosynthesis 104-105 Cercospora sp. 43 beticola 123, 136-137 cereal barley powdery mildew (ERYSGH) 30, 41, 60-61, 64, 92, 93, 94, 104, 127 fungicide resistance 123-124, 139 bunt 5, 6-7 ergot (Claviceps purpurea) 5, 172 eyespot 41, 101 fungicide market 29, 30-31 Fusarium graminearum 39 Gaeumannomyces graminis 21, 44–46, 116 leaf stripe 135 net blotch 41, 139 Pseudocercosporella herpotrichoides 62 Rhynchosporium secalis 41, 42 rust 8, 41, 64, 89, 90 septoria nodorum blotch (LEPTNO) 8, 39, 41, 113 septoria tritici blotch (SEPTRI) 8, 30–31, 39, 41, 49, 64, 90, 102, 113 fungicide resistance 139, 140, 141 wheat powdery mildew (ERYSGT) 30, 41, 64, 92, 93, 94, 104, 108, 109, 116 fungicide resistance 139

chemical nomenclature 53, 54-58 chlorophenyls 113 chlorothalonil 40, 135 chlozolinate 97 Claviceps purpurea 5, 172 clubroot (Plasmodiophora brassicae) 17,93 Colletotrichum sp. 93 lindemuthianum 16 copper 110-111, 173 Crp51 gene 130, 140–142 CrtB gene 139 curative activity 73 cymoxanil 109 cyproconazole 59, 100-101 cyprodinil 94 demethylation inhibitor (DMI) 4, 171 global sales 25-27 market 30-31 medical uses 171 mode of action (MOA) 82, 98-102 resistance 98, 100, 140-142, 146, 171, 178 Denmark 170-171 development costs 22 diagnosis 151-153 immunology 153-154 nucleic acid-based diagnostics 154-155

dicarboximides 97 dichlozoline 97 diethofencarb 87 dimethomorph 66,83 discovery 178-179 formulation 65-69 application 68-69 dust 67 emulsifiers 67-68 suspension concentrates 67 wettable powders 66, 67 screening 43 design 43 fungicide leads 50-63 high-throughput tests 48-49 in planta screens 46-47 in vivo screens 47-48 mode-of-action screens 49 primary target organisms 49-50 target selection 38-39 exploratory targets 42, 43-46 fungicide resistance 40 market deconvolution 40-43 market size 39

new diseases 39-40 new modes of action 40 re-emergent diseases 39-40 discriminatory dose (DD) 126 disease management 150 dose 155 fertilizer interactions 158-159 foliar applications 151 fungicide selection 151 diagnosis 151-155 seed treatments 150-151 soil treatments 151 timing 155-156 application frequency 157-158 disease-threat models 157 disease threshold 156-157 growth stage 156 dithiocarbamates 111 dose rate 144-146, 155 Dow 36 downy mildew 16 Plasmopora viticola (PLASVIT) 6, 34, 43, 64, 92, 105, 109, 110-111, 114 fungicide resistance 132, 142

DuPont 36

economic benefits 3-4 effective concentration (EC₅₀) 126-127 effectors 17-19 necrotrophic effectors (NEs) 18-19 PAMPs (pathogen-associated molecular patterns) 18 efflux pumps 130, 140 emulsifiers 67-68 endocrine disruption 170 environment 164-167 epoxiconazole 101 eradicant activity 73 ergot (Claviceps purpurea) 5, 172 ERYSGH (Blumeria graminis f. sp. hordei) 30, 41, 60-61, 64, 92, 93, 94, 104, 127 fungicide resistance 123-124, 139 ERYSGT (Blumeria graminis f. sp. tritici) 30, 41, 64, 92, 93, 94, 104, 108, 109, 116 fungicide resistance 139 ethaboxam 87 ethirimol 7-8,83 European Union regulation 169-171

Eutypa armeniacae 9 evespot 41, 101 fenarimol 101, 102 fenfuram 88-89 fenhexamid 104 fenpiclonil 96 fenpropidin 103-104 fenpropimorph 60-62, 103-104, 114 ferbam 111 fertilizer 3, 158-159 field resistance 127-128 monitoring 134 fitness penalty 130 fluazinam 93-94 fludioxonil 96 fluquinconazole 66 flutriafol 59 foliar treatments 68-69, 151 folpet 112-113 food production 1-2, 177-178 food safety 168 formulation 65-69 application 68-69 dust 67 emulsifiers 67-68 suspension concentrates 67 wettable powders 66, 67 fosetyl 110, 116 fuberidazole 86 fumigation 45 fungi 12-16 Ascomycota 1, 13-16 Basidiomycota 1, 16 fungicide resistance action committee (FRAC) 73, 123, 143 fungicides 1, 159-160 development costs 22 discovery 178-179 formulation 65-69 screening 43, 46-63 target selection 38-46 disease management 150 dose 155 fertilizer interactions 158-159 foliar applications 151 fungicide selection 151-155 seed treatments 150-151 soil treatments 151 timing 155-158

future prospects 177 discovery process 178-179 disease threats 177-178 food demand 177-178 fungicides loss 178 market development 180-181 plant resistance 179-180 growth 9-10 history 4-9 impact 3-4 market 21-24, 180-181 crop sectors 28-35 deconvolution 40-43 development costs 22 financial thresholds 22-24 global 24-27 manufacturers 36 UK 41-42 performance 71 mode of action (MOA) 71, 73-113 redistribution in crops 113-117 systemicity 72-73 protectant 7 redistribution in crops 113-114 phloem mobility 115–117 vapour-phase activity 114-115 regulation 162 consumer values 174 environment 164-167, 174 European Union regulation 169-171 long-term risks 169 operator safety 168 registration 163-164 residues 168 toxicology 164 resistance 31, 35, 40, 85, 87, 93, 98, 100, 123-127, 178 acylalanines 142 carboxylic acid amides (CAA) 129, 142, 178 cross-resistance 129-130 demethylation inhibitor (DMI) 98, 100, 140–142, 146, 171, 178 field resistance 127-128, 134 fitness penalty 130 fungicide resistance action committee (FRAC) 73, 123, 143 inhibition of complex III 90-93 management 143-146 medical fungi 171 methyl benzimidazole carbamate (MBC) 129, 136-137, 178

fungicides (continued) mode of resistance (MOR) 130, 134-135, 136, 140 multiple resistance 130 multi-site fungicides 135-136 quinone outside inhibitor (QoI) 31, 40, 93, 129, 135, 139, 146, 178 resistance factor (RF) 127, 128, 129-130, 139, 140, 141, 145 respiration 88 risk 131-134 sensitivity 126-127 succinate dehydrogenase inhibitor (SDHI) 130, 140, 178 succinate dehydrogenase inhibitors 88-90 uncouplers 93-94 safety 8 systemic 7 use of see disease management Fusarium graminearum 39, 142 mycotoxins 173 wilt 16

Gaeumannomyces graminis 21, 44-46, 116 global market 24-25 mode of action (MOA) 25-27 grapevine black rot (Guignardia bidwellii) 6 downy mildew (PLASVIT) 6, 34, 43, 64, 92, 105, 109, 110-111, 114 fungicide resistance 132, 142 Eutypa armeniacae 9 fungicide market 31-35 grey mould (BOTCIN) 34, 40, 42, 49, 93, 94, 95, 102, 104, 111, 113 fungicide resistance 132, 140 powdery mildew (UNCNEC) 6, 34, 92, 102, 116 fungicide resistance 139 greenhouse gas (GHG) emissions 2 guanidinium 60-62 Guignardia bidwellii 6

head blight (*Fusarium graminearum*) 39, 142 hemibiotrophs 17 host plant defence induction 107–109 hydroxyl-(2-amino-)pyrimidines 83–85 ICI 6 in planta screens 46-47 in vivo screens 47-48 inhibition of complex III 4, 8-9, 49, 90-93 global sales 25-27 market 30 mode of action (MOA) 82 performance 71 resistance 31, 40, 93 inhibition of melanin biosynthesis 105-107 inhibition of RNA synthesis hydroxyl-(2-amino-)pyrimidines 83-85 phenylamides 82-83 intellectual property 23-24 invasive aspergillosis (IA) 171 iprodione 97 isomerase and reductase inhibitors 102-104 isopyrazam 90 isotianil 109

3-ketoreductase 104 kresoxim-methyl 92

LD₅₀ 164 leaching 165-166 leaf stripe (Pyrenophora graminea) 135 legislation 162 consumer values 174 environment 164-167, 174 European Union regulation 169-171 long-term risks 169 operator safety 168 registration 163-164 residues 168 toxicology 164 LEPTNO (Parastagonospora nodorum) 8, 39, 41, 113 $\log P 63$ long-term risks 169 Lysimeter methodology 165–166

Magnaporthe oryzae (PYRIOR) 16, 29–30, 42, 53, 64, 102, 106–107, 109 MAI 36 management of resistance 143 alternation 146 dose rate 144–146 good hygiene 143–144

integrated disease management 144 mixtures 146 mancozeb 34 market 21-24, 180-181 crop sectors 28 cereals 29-31 grapevine 31-35 pome (top) fruit 35 deconvolution 40-43 development costs 22 financial thresholds 22-24 global 24-25 mode of action (MOA) 25-27 manufacturers 36 UK 41-42 mepanipyrim 94 mepronil 89 mercury 135 metalaxyl 82, 114, 142 methyl benzimidazole carbamate (MBC) 4,85-87 resistance 129, 136-137, 178 mitosis and cell division benzamides 87 phenylcarbamates 87 β-tubulin assembly 85-87 mode of action (MOA) 7 amino acid synthesis anilinopyrimidines 94 cell wall biosynthesis 104-105 global market 25-27 host plant defence induction 107-109 inhibition of melanin biosynthesis 105-107 inhibition of RNA synthesis hydroxyl-(2-amino-)pyrimidines 83-85 phenylamides (PA) 82-83 mitosis and cell division benzamides 87 phenylcarbamates 87 β-tubulin assembly 85-87 multi-site chlorophenyls 113 copper 110-111 dithiocarbamates 111 phthalimides 112-113 sulfur 111 performance 71, 73-82 amino acid synthesis 94 cell wall biosynthesis 104-105 host plant defence induction 107-109 inhibition of melanin biosynthesis 105-107

inhibitic l

inhibition of RNA synthesis 82-85 mitosis and cell division 85-87 multi-site 109-113 respiration 88-94 signal transduction 95-97 sterol biosynthesis 97-104 unknown 109-110 resistance see resistance respiration 88 inhibition of complex III 90-93 succinate dehydrogenase inhibitors 88-90 uncouplers 93-94 screening 49 signal transduction azanaphthalenes 95 dicarboximides 97 phenylpyrroles 96 sterol biosynthesis inhibitors (SBIs) 97-98 C14-demethylation inhibitors (DMIs) 98-102 isomerase and reductase inhibitors 102-104 3-ketoreductase 104 unknown cymoxanil 109 fosetyl 110 mode of resistance (MOR) 130, 136, 140 determining 134-135 Monsanto 36 multi-site modes of action chlorophenyls 113 copper 110-111 dithiocarbamates 111 phthalimides 112-113 sulfur 111 MYCFIJ (Mycosphaerella fijiensis) 49, 64, 102, 110–111 fungicide resistance 132 Mycosphaerella fijiensis (MYCFIJ) 49, 64, 102, 110-111 fungicide resistance 132 mycotoxins 172-173

necrotrophic effectors (NEs) 18–19 necrotrophs 17 net blotch 41, 139 nomenclature 19 nuarimol 102 Nufarm 36 obligate pathogens 49 Oomycota 1, 11–12, 16–17 operator safety 168 organic farming 171–174

PAMPs (pathogen-associated molecular patterns) 18 Parastagonospora nodorum (LEPTNO) 8, 39, 41.113 patents 23-24 penflufen 90 performance 71 mode of action (MOA) 71, 73-82 amino acid synthesis 94 cell wall biosynthesis 104-105 host plant defence induction 107-109 inhibition of melanin biosynthesis 105-107 inhibition of RNA synthesis 82-85 mitosis and cell division 85-87 multi-site 109-113 respiration 88-94 signal transduction 95-97 sterol biosynthesis 97-104 unknown 109-110 redistribution in crops 113-114 phloem mobility 115-117 vapour-phase activity 114-115 systemicity 72-73 Peronospora 16 Phakopsora pachyrhizi 39-40 phenylamides (PA) 82-83, 178 phenylcarbamates 87 phenylpyrroles 96 phloem mobility 115-117 phthalimides 112-113 PHYTIN (Phytophthora infestans) 5, 40, 64, 93, 105, 109, 110-111, 113 fungicide resistance 123, 132, 142 Phytophthora 1, 110 cinnamomi 109-110 infestans (PHYTIN) 5, 40, 64, 93, 105, 109, 110–111, 113 fungicide resistance 123, 132, 142 plant disease 11-16 plant resistance 179-180 Plasmodiophora 1, 11-12, 17 brassicae 17,93 Plasmopara viticola (PLASVIT) 6, 34, 43, 64, 92, 105, 109, 110-111, 114 fungicide resistance 132, 142

PLASVIT (Plasmopara viticola) 6, 34, 43, 64, 92, 105, 109, 110-111, 114 fungicide resistance 132, 142 Podosphaera leucotricha 35, 42, 102 pome (top) fruit Alternaria mali 35 apple scab (VENTIN) 6, 16, 35, 42, 49, 64, 93, 94, 102, 111, 113 fungicide market 35 powdery mildew (Podosphaera leucotricha) 35, 42, 102 population growth 1-2 potato blight (PHYTIN) 5, 40, 64, 93, 105, 109, 110-111, 113 fungicide resistance 123, 132, 142 Synchytrium endobioticum 13 powderv mildew 110-111 ERYSGH (Blumeria graminis f.sp. hordei) 30, 41, 60-61, 64, 92, 93, 94, 104, 127 fungicide resistance 123-124, 139 ERYSGT (Blumeria graminis f.sp. tritici) 30, 41, 64, 92, 93, 94, 104, 108, 109, 116 fungicide resistance 139 fungicide resistance 123-124, 139, 131, 132, 139 Podosphaera leucotricha 35, 42, 102 Sphaerotheca fuliginea 6 UNCNEC (Uncinula necator) 6, 34, 92, 102, 116 fungicide resistance 139 probenazole 107 prochloraz 66, 101-102 procymidone 97 propiconazole 101 propimorph 114 proquinazid 95 protectant activity 7, 72-73 prothioconazole 40, 59, 101 Pseudocercosporella herpotrichoides 62 Puccinia hordei 41 recondita (PUCCRT) 8, 64, 89, 90 striiformis 41 PUCCRT (Puccinia recondita) 8, 64, 89, 90 pyraclostrobin 92 Pyrenophora graminea 135 teres 41, 139 tritici-repentis 139

pyrimethanil 94 PYRIOR (*Magnaporthe oryzae*) 16, 29–30, 42, 53, 64, 102, 106–107, 109 Pythium 1, 16, 105

quinone outside inhibitor (QoI) 4, 8–9, 49, 90–93 global sales 25–27 market 30 mode of action (MOA) 82 performance 71 resistance 31, 40, 93, 129, 135, 139, 146, 178 quinoxyfen 49, 95, 116, 167, 168

random screening 51-52 redistribution 61-62 regulation 162 consumer values 174 environment 164-167, 174 European Union regulation 169-171 long-term risks 169 operator safety 168 registration 163-164 residues 168 toxicology 164 residues 168 resistance 31, 35, 40, 85, 87, 93, 98, 100, 123-127, 178 acylalanines 142 carboxylic acid amides (CAA) 129, 142, 178 cross-resistance 129-130 demethylation inhibitor (DMI) 98, 100, 140-142, 146, 171, 178 field resistance 127-128 monitoring 134 fitness penalty 130 fungicide resistance action committee (FRAC) 73, 123, 143 inhibition of complex III 90-93 management 143 alternation 146 dose rate 144-146 good hygiene 143-144 integrated disease management 144 mixtures 146 medical fungi 171 methyl benzimidazole carbamate (MBC) 129, 136–137, 178 mode of resistance (MOR) 130, 136, 140 determining 134-135

multiple resistance 130 multi-site fungicides 135-136 quinone outside inhibitor (QoI) 31, 40, 93, 129, 135, 139, 146, 178 resistance factor (RF) 127, 128, 129-130, 139, 140, 141, 145 respiration 88 risk 131 fungicide risk factors 133-134 pathogen risk factors 131-133 sensitivity 126-127 succinate dehydrogenase inhibitor (SDHI) 88-90, 130, 140, 178 uncouplers 93-94 Rhizoctonia sp. 42 solani 62, 89 Rhynchosporium secalis 41, 42 rice blast (PYRIOR) 16, 29-30, 42, 53, 64, 102, 106-107, 109 fungicide market 29-30 rust 6 fungicide resistance 133 Phakopsora pachyrhizi 39-40 Puccinia bordei 41 recondita (PUCCRT) 8, 64, 89,90

Saccharomyces cerevisiae 50 salicylic acid 107 Sclerotinia sp. 43, 93, 97 screening 43 design 43 fungicide leads 50-51 analogue synthesis 52-53 biorational design 59-62 chemorational design 62-63 combinatorial chemistry 52 random screening 51-52 high-throughput tests 48-49 in planta screens 46-47 in vivo screens 47-48 methodology 63-65 mode-of-action screens 49 primary target organisms 49-50 sedaxane 90 seed treatments 6-7, 30, 45, 68, 88-90, 150-151 sensitivity 126-127

striiformis 41

septoria nodorum blotch (LEPTNO) 8, 39, 41, 113 septoria tritici blotch (SEPTRI) 8, 30-31, 39, 41, 49, 64, 90, 102, 113 fungicide resistance 139, 140, 141 SEPTRI (Zymoseptoria tritici) 8, 30-31, 39, 41, 49, 64, 90, 102, 113 fungicide resistance 139, 140, 141 sequence variation 138 signal transduction azanaphthalenes 95 dicarboximides 97 phenylpyrroles 96 soil fungicides 45, 151 soybean rust (Phakopsora pachyrhizi) 39-40 Sphaerotheca fuliginea 6 spiroxamine 103 spreaders 67-68 sterol biosynthesis inhibitors (SBIs) 97-98 C14-demethylation inhibitors (DMIs) 98-102 isomerase and reductase inhibitors 102-104 3-ketoreductase 104 strobilurins 52, 90-93 succinate dehydrogenase inhibitor (SDHI) 9 global sales 27 market 30 mode of action (MOA) 82, 88-90 performance 71 resistance 88-90, 130, 140, 178 sulfur 34, 111, 114, 173 suspension concentrates 67 Synchytrium endobioticum 13 Syngenta 10, 36 systemic acquired resistance (SAR) 107-109 systemic activity 7, 72-73

take-all (*Gaeumannomyces graminis*) 21, 44–46, 116 target selection 38–39 exploratory targets 42, 43–46 fungicide resistance 40 market deconvolution 40–43 market size 39 new diseases 39–40 new modes of action 40 re-emergent diseases 39–40 tebuconazole 101, 127 thiabendazole 86 thiophanate-methyl 85 thiram 111 tiadinil 109 Tilletia tritici 5, 6–7 timing 155–156 application frequency 157-158 disease-threat models 157 disease threshold 156-157 growth stage 156 top fruit see pome fruit toxicology 164 transgenic (GM) disease control 179-180 triazole 8, 40, 53, 101 market 30 tricyclazole 29, 53, 106-107 tridemorph 7-8, 103-104 trifloxystrobin 92 β-tubulin assembly 85-87 fungicide resistance 130, 137 Typhula incarnata 89

UK 171 market 41–42 Uncinula necator (UNCNEC) 6, 34, 92, 102, 116 fungicide resistance 139 UNCNEC (Uncinula necator) 6, 34, 92, 102, 116 fungicide resistance 139 uncouplers 93–94 unknown mode of action cymoxanil 109 fosetyl 110 Ustilago maydis 140

vapour-phase activity 114–115 VENTIN (Venturia inaequalis) 6, 16, 35, 42, 49, 64, 93, 94, 102, 111, 113 Venturia inaequalis (VENTIN) 6, 16, 35, 42, 49, 64, 93, 94, 102, 111, 113 vinclozolin 97

wettable powders 66, 67

zineb 111 ziram 111 zoxamide 87 *Zymoseptoria tritici* (SEPTRI) 8, 30–31, 39, 41, 49, 64, 90, 102, 113 fungicide resistance 139, 140, 141